ReViral, a clinical-stage biopharmaceutical company focused on discovering and developing antiviral therapeutics that target (RSV) respiratory syncytial virus has confirmed the FDA has granted Fast Track designation to Sisunatovir.

Sisunatovir is orally administered and is for the treatment of patients with serious RSV infection. Richmond Pharmacology is proud to have supported the development by conducting the First in Human Study earlier in the drug development.

RSV affects approximately 64 million people and causes approximately 160,000 deaths each year. Fast Track is a process intended to facilitate the development and expediate the review of drug candidates that treat serious conditions and fill an unmet medical need.

Latest news

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Employee Well-Being: A Commitment that Defines Richmond

October 2, 2023
Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.
Read more

Events

ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event